相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis
Maria R. Emma et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2020)
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
Silvano Fasolato et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
Effects of immunization against PCSK9 in an experimental model of breast cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT
Wen-Kai Shi et al.
CELL DEATH & DISEASE (2018)
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target
Cheng-Dong Qin et al.
CELL DEATH & DISEASE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition
Jian'an Bai et al.
ONCOTARGET (2017)
The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Xiao-Xiao He et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2017)
Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment
Robert Dufour et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Network analyses identify liver-specific targets for treating liver diseases
Sunjae Lee et al.
MOLECULAR SYSTEMS BIOLOGY (2017)
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
Xiaohui Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance The GAUSS-3 Randomized Clinical Trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2
De-Ning Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans
Lei Li et al.
JOURNAL OF HEPATOLOGY (2016)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice
Majambu Mbikay et al.
JOURNAL OF DIABETES (2015)
Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype
Zuhier Awan et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies et al.
PLOS ONE (2012)
Hepatitis C virus entry: beyond receptors
Luke W. Meredith et al.
REVIEWS IN MEDICAL VIROLOGY (2012)
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Xiaowei Sun et al.
NEOPLASIA (2012)
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
Paola Lo Surdo et al.
EMBO REPORTS (2011)
Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor
Sha Huang et al.
JOURNAL OF LIPID RESEARCH (2010)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Fatty acid metabolism in breast cancer cells:: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
Teresa Puig et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Proapoptotic effects of NARC 1 (=PCSK9), the gene encoding a novel serine proteinase
Brendan Bingham et al.
CYTOMETRY PART A (2006)
Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system
Steve Poirier et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity
SJ Kridel et al.
CANCER RESEARCH (2004)
Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics
Y Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver
SW Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
